Tamoxifen

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

Volumn 66, Issue , 1996, Pages 253-365

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CARCINOGEN; TAMOXIFEN;

ANIMAL; CARCINOGEN TESTING; HUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOGENICITY TESTS; CARCINOGENS; ESTROGEN ANTAGONISTS; HUMANS; TAMOXIFEN;

EID: 0030321284     PISSN: 02509555     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (394)

1. Adam, H.K., Patterson, J.S. & Kemp, J.V. (1980) Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treatment Rep., 64, 761-764
2. Ahotupa, M., Hirsimäki, P., Pärssinen, R. & Mäntylä, E. (1994) Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat. Carcinogenesis, 15, 863-868
3. Akhtar, S.S., Allan, S.G., Rodger, A., Chetty, U.D.I., Smyth, J.F. & Leonard, R.C.F. (1991) A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur. J. surg. Oncol., 17, 30-35
4. Altaras, M.M., Aviram, R.,. Cohen, I., Cordoba, M., Yarkoni, S. & Beyth, Y. (1993) Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Gynecol. Onco., 49, 255-258
5. Andersson, M., Storm, H.H. & Mouridsen, H.T. (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J. natl Cancer Inst., 83, 1013-1017
6. Andersson, M., Storm, H.H. & Mouridsen, H.T. (1992) Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta oncol., 31, 259-263
7. Anker, G., Lønning, P.E., Ueland, P.M., Refsum, H. & Lien, E.A. (1995) Plasma levels of the antherogenic amino acid homocysteine in post-menopausal women treated with tamoxifen. Int. J. Cancer, 60, 365-368
8. Ashford, A.R., Donev, I., Tiwari, R.P. & Garrett, T.J. (1988) Reversible ocular toxicity related to tamoxifen therapy. Cancer, 61, 33-35
9. Atlante, G., Pozzi, M., Vincenzoni, C. & Vocaturo, G. (1990) Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol. Oncol., 37, 378-380
10. Bagdade, J.D., Wolter, J., Subbaiah, P.V. & Ryan, W. (1990) Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J. clin. Endocrinol. Metab., 70, 1132-1135
11. Baltuch, G., Shenouda, G., Langleben, A. & Villemure, J.-G. (1993) High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilization and tumour regression. Can. J. neurol. Sci., 20, 168-170
12. Barakat, R.R. & Hoskins, W.J. (1994) Current management of endometrial cancer. Contemporary Ob./Gyn., 39, 13-34
13. Barakat, R.R., Wong, G., Curtin, J.P., Vlamis, V. & Hoskins, W.J. (1994) Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol. Oncol., 55, 164-168
14. Bardi, M., Arnoldi, E., Pizzocchero, G., Pezzica, E., Mattioni, D. & Perotti, M. (1994) Endometrioid carcinoma in pelvic endometriosis in a postmenopausal woman with tamoxifen adjuvant therapy for breast cancer. A case report. Eur. J. Gynaec. Oncol., 15, 393-395
15. Bates, T., Riley, D.L., Houghton, J., Fallowfield, L. & Baum, M. (on behalf of the Elderly Breast Cancer Working Party) (1991) Breast Cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br. J. Surg., 78, 591-594
16. Baum, M., Houghton, J. & Riley, D. (1992) Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer reported at the tenth year of follow-up. Acta oncol., 31, 251-257
17. Bedford, G.R. & Richardson, D.N. (1966) Preparation and identification of cis and trans isomers of a substituted triarylethylene. Nature, 212, 733-734
18. Beer, T.W., Buchanan, R. & Buckley, C.H. (1995) Uterine stromal sarcoma following tamoxifen treatment (Letter to the Editor). J. clin. Pathol., 48, 596
19. Beggs, W.H. (1993) Anti-candida activity of the anti-cancer drug tamoxifen. Res. Comm. chem. Pathol. Pharmacol., 80, 125-128
20. Bertelli, G., Pronzato, P., Amoroso, D., Cusimano, M.P., Conte, P.F., Montagna, G., Bertolini, S. & Rosso, F. (1988) Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res. Treat., 12, 307-310
21. Berthou, F. & Dréano, Y. (1993) High-performance liquid Chromatographic analysis of tamoxifen, toremifene and their major human metabolites. J. Chromatogr., 616, 117-127
22. Beyer, B.K., Stark, K.L., Fantel, A.G. & Juchau, M.R. (1989) Biotransformation, estrogenicity and steroid structure as determinants of dysmorphogenic and generalized embryotoxic effects of steroidal and nonsteroidal estrogens. Toxicol. appl. Pharmacol., 98, 113-127
23. Boccardo, F., Bruzzi, P., Rubagotti, A., Nicolò, G. & Rosso, R. (1981) Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology, 38, 281-285
24. Boccardo, F., Amoroso, D., Rubagotti, A., Capellini, M., Pacini, P., Castagnetta, L., Traina, A., Farris, A., Iacobelli, S., Mustacchi, G., Nenci, I., Piffanelli, A., Sismondi, P., De Sanctis, C., Mesiti, M., Gallo, L., Villa, E. & Schieppati, G. (1994a) Prolonged tamoxifen treatment of early breast cancer: the experience of the Italian Cooperative Group for chemohormonal therapy of early breast cancer. In: Jordan, V.C., ed., Long-Term Tamoxifen Treatment for Breast Cancer, Madison, WI, The University of Wisconsin Press
25. Boccardo, F., Rubagotti, A., Perrotta, A., Amoroso, D., Balestrero, M., De Matteis, A., Zola, P., Sismondi, P., Francini, G., Petrioli, R., Sassi, M., Pacini, P. & Galligioni, E. (1994b) Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann. Oncol., 5, 337-342
26. Bocklage, T., Lee, K.R. & Belinson, J.L. (1992) Uterine Müllerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy. Gynecol. Oncol., 44, 104-109
27. Branham, W.S., Zehr, D.R., Chen, J.J. & Sheehan, D.M. (1988) Alterations in developing rat uterine cell populations after neonatal exposure to estrogens and antiestrogens. Teratology, 38, 271-279
28. Branham, W.S., Zehr, D.R. & Sheehan, D.M. (1993) Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens. Proc. Soc. exp. Biol. Med., 203, 297-303
29. Breast Cancer Chemotherapy Consensus Conference (1985) Adjuvant chemotherapy for breast cancer. J. Am. med. Assoc., 254, 3461-3463
30. Breast Cancer Trials Committee (1987) Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet, ii, 171-175
31. British Medical Association/Royal Pharmaceutical Society of Great Britain (1994) British National Formulary Number 27 (March 1994), London, p. 329
32. British Pharmacopoeial Commission (1993) British Pharmacopoeia 1993, Vols. I & II, London, Her Majesty's Stationery Office, pp. 650-651, 1119-1120
33. Brooks, M.D., Ebbs, S.R., Colletta, A.A. & Baum, M. (1992) Desmoid tumours treated with triphenylethylenes. Eur. J. Cancer, 28A, 1014-1018
34. Bruning, P.F., Bonfrer, J.M.G., Hart, A.A.M., de Jong-Bakker, M., Linders, D., van Loon, J. & Nooyen, W.J. (1988) Tamoxifen, serum lipoproteins and cardiovascular risk. Br. J. Cancer, 58, 497-499
35. Buchanan, R.B., Blamey, R.W., Durrant, K.R., Howell, A., Paterson, A.G., Preece, P.E., Smith, D.C., Williams, C.J. & Wilson, R.G. (1986) A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J. clin. Oncol., 4, 1326-1330
36. Buckley, C.H. (1990) Tamoxifen and endometriosis. Case report. Br. J. Obstet. Gynaecol., 97, 645-646
37. Buckley, M.M.-T. & Goa, K.L. (1989) Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs, 37, 451-490
38. Budavari, S., ed. (1995) The Merck Index, 12th Ed., Rahway, NJ, Merck & Co.
39. Burke, P., Fasciano, F., Frigerio, A., Temporelli, A. & Fortunati, N. (1987) Ultrasonography study of postmenopausal uterus in patients treated with tamoxifen. Min. gin., 39, 453-457 (in Italian)
40. Butta, A., MacLennan, K., Flanders, K.C., Sacks, N.P.M., Smith, I., McKinna, A., Dowsett, M., Wakefield, L. M., Sporn, M.B., Baum, M. & Colletta, A.A. (1992) Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res., 52, 4261-4264
41. Cano, A., Matallin, P., Legua, V., Tortajada, M. & Bonilla-Musoles, F. (1989) Tamoxifen and endometriosis (Letter to the Editor). Lancet, i, 376
42. Carmichael, P.L., Ugwumadu, A.H.N., Neven, P., Hewer, A.J., Poon, G.K. & Phillips, D.H. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res., 56, 1475-1479
43. Carthew, P., Martin, E.A., White, I.N.H., De Matteis, F., Edwards, R.E., Dorman, B.M., Heydon, R.T. & Smith, L.L. (1995a) Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res., 55, 544-547
44. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis, 16, 1299-1304
45. Castiglione, M., Gelber, R.D. & Goldhirsch, A. (1990) Adjuvant systemic therapy for breast cancer in the elderly; competing causes of mortality. J. clin. Oncol., 8, 519-526
46. Chamart, S., Hanocq, M., Helson, M., Devleeschouwer, N. & Leclercq, G. (1989) Determination of 2-methyl derivatives of tamoxifen in cell culture medium using high-performance liquid chromatography and electrochemical detection. J. Chromatogr., 496, 365-375
47. Chamness, G.C., Bannayan, G.A., Landry, L.A., Jr, Sheridan, P.J. & McGuire, W.L. (1979) Abnormal reproductive development in rats after neonatally administered antioestrogen (tamoxifen). Biol. Reprod., 21, 1087-1090
48. Champion, P.E., Nabholtz, M., Jenkins, H., MacLean, G., Allen, S. & Lees, A. (1991) Is tamoxifen increasing the risk of uterine malignancy in women treated for breast cancer ? (Abstract). Breast Cancer Res. Treat., 19, 195
49. Chang, T., Gonder, J.R. & Ventresca, M.R. (1992) A case-report. Low-dose tamoxifen retinopathy. Can. J. Ophthalmol., 27, 148-149
50. Ching, C.K., Smith, P.G. & Long, R.G. (1992) Tamoxifen-associated hepatocellular damage and agranulocytosis (Letter to the Editor). The Lancet, 339, 940
51. Chou, Y.-C., Iguchi, T. & Bern, H.A. (1992) Effects of antiestrogens on adult and neonatal mouse reproductive organs. Reprod. Toxicol., 6, 439-446
52. Clark, J.H., Guthrie, S.C. & McCormack, S.A. (1981) Neonatal stimulation of the uterus by clomiphene, tamoxifen and nafoxidine: relationship to the development of reproductive tract abnormalities. Adv. exp. Med. Biol., 138, 87-98
53. Clarke, M.R. (1993) Uterine malignant mixed Müllerian tumor in a patient on long-term tamoxifen therapy for breast cancer. Gynecol. Oncol., 51, 411-415
54. Coco, C.M., Hargis, B.M. & Hargis, P.S. (1992) Effect of in ovo 17β-estradiol or tamoxifen administration on sexual differentiation of the external genitalia. Poultry Sci., 71, 1947-1951
55. Coe, J.E., Ishak, K.G., Ward, J.M. & Ross, M.J. (1992) Tamoxifen prevents induction of hepatic neoplasia by zeranol, an estrogenic food contaminant. Proc. natl Acad. Sci. USA, 89, 1085-1089
56. Cohen, I., Altaras, M.M., Lew, S., Tepper, R., Beyth, Y. & Ben-Baruch, G. (1994) Case Report. Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature. Gynecol. Oncol., 55, 443-447
57. Cole, M.P., Jones, C.T.A. & Todd, I.D.H. (1971) A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46 474. Br. J. Cancer, 25, 270-275
58. Collyn-d'Hooghe, M., Vandewalle, B., Hornez, L., Lantoine, D., Revillion, F., Lefebvre, J. & Kerckaert, J. P. (1991) c-myc Overexpression, c-mil, c-myb expression in a breast tumor cell line. Effects of estrogen and antiestrogen. Anticancer Res., 11, 2175-2180
59. Cook, L.S., Weiss, N.S., Schwartz, S.M., White, E., McKnight, B., Moore, D.E. & Daling, J.R. (1995) Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J. natl Cancer Inst., 87, 1359-1364
60. Corley, D., Rowe, J., Curtis, M.T., Hogan, W.M., Noumoff, J.S. & LiVolsi, V.A. (1992) Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet. Gynecol., 79, 111-116
61. Cortez Pinto, H., Baptista, A., Ermelinda Camilo, M., Bruno de Costa, E., Valente, A. & Carneiro de Moura, M. (1995) Tamoxifen-associated steatohepatitis - report of three cases. J. Hepatol., 23, 95-91
62. Costa, A., Sacchini, V., Boranni, B., Luini, A., Boyle, P., Rofmensz, N., Veronesi, U. & the Italian Tamoxifen Trial Units (1996) Breast cancer chemoprevention with tamoxifen. The Italian trial (Abstract). Breast Cancer Res. Treat., 37, 348
63. Council of Europe (1995) European Pharmacopoeia, 2nd Ed., Part II, 19th fasc., Sainte-Ruffine, France, Maisonneuve S.A., pp. 1046-1-1046-4
64. Crofton-Sleigh, C., Doherty, A., Ellard, S., Parry, E.M. & Venitt, S. (1993) Micronucleus assays using cytochalasin-blocked MCL-5 cells, a proprietary human cell line expressing five human cytochromes P-450 and microsomal epoxide hydrolase. Mutagenesis, 8, 363-372
65. Cross, S.S. & Ismail, S.M. (1990) Endometrial hyperplasia in an oophorectomized women receiving tamoxifen therapy. Case report. Br. J. Obstet. Gynaecol., 97, 190-192
66. Cullins, S.L., Pridjian, G. & Sutherland, C.M. (1994) Goldenhar's syndrome associated with tamoxifen given to the mother during gestation. J. Am. med. Assoc., 271, 1905-1906
67. Cummings, F.J., Gray, R., Tormey, D.C., Davis, T.E., Volk, H., Harris, J., Falkson, G. & Bennett, J.M. (1993) Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J. clin. Oncol., 11, 29-35
68. Cunha, G.R., Taguchi, O., Namikawa, R., Nishizuka, Y. & Robboy, S.J. (1987) Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract. Hum. Pathol., 18, 1132-1143
69. Curtis, R.E., Boice, J.D., Jr, Shriner, D.A., Hankey, B.F. & Fraumeni, J.F., Jr (1996) Second cancers after adjuvant tamoxifen therapy for breast cancer. Brief communication. J. natl Cancer Inst. (in press)
70. Cuzick, J., Allen, D., Baum, M., Barrett, J., Clark, G., Kakkar, V., Melissari, E., Moniz, C., Moore, J., Parsons, V., Pemberton, K., Pitt, P., Richmond, W., Houghton, J. & Riley, D. (1993) Long term effects of tamoxifen. Biological Effects of Tamoxifen Working Party. Eur. J. Cancer, 29A, 15-21
71. Dallenbach-Hellweg, G. & Hahn, U. (1995) Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens. Int. J. gynecol. Pathol., 14, 7-15
72. Daniel, P., Gaskell, S.J., Bishop, H., Campbell, C. & Nicholson, R.I. (1981) Determination of tamoxifen and biologically active metabolites in human breast tumour and plasma. Eur. J. Cancer clin. Oncol., 17, 1183-1189
73. Dauplat, J., Le Bouëdec, G. & Achard, J.L. (1990) Adenocarcinoma of the endometrium in two patients treated with tamoxifen, Presse méd., 19, 380-381 (in French)
74. Davies, A.M., Martin, E.A., Jones, R.M., Lim, C.K., Smith, L.L. & White, I.N.H. (1995) Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis, 16, 539-545
75. De Jong-Busnac, M. (1989) Ophthamological complications of low-dose tamoxifen in the treatment of breast cancer. Ned. Tijdschr. Geneesk., 133, 514-516 (in Dutch)
76. De Muylder, X., Neven, P., De Somer, M., Van Belle, Y., Vanderick, G. & De Muylder, E. (1991) Endometrial lesions in patients undergoing tamoxifen therapy. Int. J. gynecol. Obstet., 36, 127-130
77. Deprest, J., Neven, P. & Ide, P. (1992) An unusual type of endometrial cancer, related to tamoxifen? Eur. J. Obstet. Gynecol. reprod. Biol., 46, 147-150
78. Dewar, J.A., Horobin, J.M., Preece, P.E., Tavendale, R., Tunstall-Pedoe, H. & Wood, R.A.B. (1992) Long term effects of tamoxifen on blood lipid values in breast cancer. Br. med. J., 305, 225-226
79. Dilts, P.V., Jr, Hopkins, M.P., Chang, A.E. & Cody, R.L. (1992) Rapid growth of leiomyoma in patient receiving tamoxifen. Am. J. Obstet. Gynecol., 166, 167-168
80. Dnistrian, A.M., Schwartz, M.K., Greenberg, E.J., Smith, C.A. & Schwartz, D.C. (1993) Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy. Clin. chim. Acta, 223, 43-52
81. Dragan, Y.P., Rizvi, T., Xu, Y.-H., Hully, J.R., Bawa, N., Campbell, H.A., Maronpot, R.R. & Pilot, H.C. (1991a) An initiation-promotion assay in rat liver as a potential complement to the 2-year carcinogenesis bioassay. Fundam. appl. Toxicol., 16, 525-547
82. Dragan, Y.P., Xu, Y.-D. & Pilot, H.C. (1991b) Tumor promotion as a targel for estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prev. Med., 20, 15-26
83. Dragan, Y.P., Fahey, S., Street, K., Vaughan, J., Jordan, V.C. & Pilot, H.C. (1994) Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res. Treat., 31, 11-25
84. Dragan, Y.P., Vaughan, J., Jordan, V.C. & Pilot, H.C. (1995) Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. Carcinogenesis, 16, 2733-2741
85. Early Breast Cancer Trialists' Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytoloxic therapy on mortalily in early breast cancer. An overview of 61 randomized trials among 28,896 women. New Engl. J. Med., 319, 1681-1692
86. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet, 339, 1-15, 71-85
87. Enck, R.E. & Rios, C.N. (1984) Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer, 53, 2607-2609
88. Enevoldson, T.P. & Harding, A.E. (1992) Improvement in the POEMS syndrome after administration of tamoxifen (Letter to the Editor). J. Neurol. Neurosurg. Psychiat., 55, 71-72
89. Esaki, K. & Sakai, Y. (1980) Tamoxifen; influence of oral administration of tamoxifen on the rabbit fetus. Jitchukan Zenrinsho Kenkyuho, 6, 217-231 (in Japanese)
90. Evans, M.J., Langlois, N.E.I., Kitchener, H.C. & Miller, I.D. (1995) Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of Ihe uterus? Int. J. Gynecol. Cancer, 5, 310-313
91. Farmindustria (1993) Repertorio Farmaceutico Italiano (Italian Pharmaceutical Directory), 7th Ed., Milan, Associazione Nazionale dell'Industria Farmaceutica, CEDOF, S.P.A., pp. A-794-A795; A-1101-A-1102
92. Fendl, K.C. & Zimniski, S.J. (1992) Role of tamoxifen in the induction of hormone-independent rat mammary tumours. Cancer Res., 52, 235-237
93. Fentiman, I.S., Caleffi, M., Rodin, A., Murby, B. & Fogelman, I. (1989) Bone mineral content of women receiving tamoxifen for mastalgia. Br. J. Cancer, 60, 262-264
94. Ferrazzi, E., Cartei, G., Mattarazzo, R. & Fiorentino, M. (1977) Oestrogen-like effect of tamoxifen on vaginal epithelium (Letter to the Editor). Br. med. J., i, 1351-1352
95. Fisher, B., Redmond, C., Brown, A., Fisher, E.R., Wolmark, N., Bowman, D., Plotkin, D., Wolter, J., Bornstein, R., Legault-Poisson, S., Saffer, E.A. & Other NSABP Investigators (1986) Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J. clin. Oncol., 4, 459-471
96. Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N.V., Wolmark, N., Wickerham, D.L., Fisher, E.R., Margolese, R., Robidoux, A., Shibata, H., Terz, J., Paterson, A.H.G., Feldman, M.I., Fararr, W., Evans, J., Lickley, H.L. & Keiner, R.N. (1989a) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. New Engl. J. Med., 320, 479-484
97. Fisher, B., Redmond, C., Wickerham, L., Wolmark, N., Bowman, D., Couture, J., Dimitrov, N.V., Margolese, R., Legault-Poisson, S. & Robidoux, A. (1989b) Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials. Ann. intern. Med., 111, 703-712
98. Fisher, B., Costantino, J.P., Redmond, C.K., Fisher, E.R., Wickerham, D.L. & Cronin, W.M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. natl Cancer Inst., 86, 527-537
99. Folk, J.J., Mazur, M.T., Eddy, G.L. & Musa, A.G. (1995) Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case. Gynecol. Oncol., 58, 133-135
100. Ford, M.R., Turner, M.J., Wood, C. & Soutter, W.P. (1988) Endometriosis developing during tamoxifen therapy. Am. J. Obstet. Gynecol., 158, 119
101. Fornander, T., Rutqvist, L.E., Cedermark, B., Glas, U., Mattsson, A., Silfverswärd, C., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J. & Hjalmar, M.-L. (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, i, 117-120
102. Fornander, T., Rutqvist, L.E., Sjöberg, H.E., Blomqvist, L., Mattsson, A. & Glas, U. (1990) Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in post-menopausal women. J. clin. Oncol., 8, 1019-1024
103. Fornander, T., Rutqvist, L.E., Cedermark, B., Glas, U., Mattsson, A., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J., Rotstein, S., Hjalmar, M.-L. & Perbeck, L. (1991) Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J. clin. Oncol., 9, 1740-1748
104. Fornander, T., Hellström, A.-C. & Moberger, B. (1993) Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J. natl Cancer Inst., 85, 1850-1855
105. Forsberg, J.G. (1985) Treatment with different antioestrogens in the neonatal period and effects in the cervicovaginal epithelium and ovaries of adult mice: a comparison to estrogen-induced changes. Biol. Reprod., 32, 427-441
106. Foster, W.G., Jarrell, J.F. & YoungLai, E.V. (1993) Developmental changes in the gonadotropin releasing hormone neuron of the female rabbit: effects of tamoxifen citrate and pregnant mare serum gonadotropin. Can. J. Physiol. Pharmacol., 71, 761-767
107. Fried, K.M. & Wainer, I.W. (1994) Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography J. Chromatogr. B, 655, 261-268
108. Fromson, J.M., Pearson, S. & Bramah, S. (1973a) The metabolism of tamoxifen (ICI 46,474). Part II: In female patients. Xenobiotica, 3, 711-714
109. Fromson, J.M., Pearson, S. & Bramah, S. (1973b) The metabolism of tamoxifen (ICI 46,474). Part I: In laboratory animals. Xenobiotica, 3, 693-709
110. Furr B.J.A. & Jordan, V.C. (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25, 127-205
111. Furr, B.J.A., Valcaccia, B. & Challis, J.R.G. (1976) The effects of nolvadex (tamoxifen citrate; ICI 46,474) on pregnancy in rabbits. J. Reprod. Fert., 48, 367-369
112. Furr, B.J.A., Patterson, J.S., Richardson, D.N., Slater, S.R. & Wakeling, A.E. (1979) Tamoxifen. In: Goldberg, M.E., ed., Pharmacological and Biochemical Properties of Drug Substances, Washington, American Pharmacological Association, Vol. II, pp. 355-399
113. Gennaro, A.R., ed. (1995) Remington: The Science and Practice of Pharmacy, 19th Ed., Vol. II, Easton, PA, Mack Publishing Co., p. 1094
114. Gershbein, L.L. (1994) Induction of colon adenocarcinomas in rats fed trypsin and tamoxifen diets by parenteral and intragastric 1,2-dimethylhydrazine. Res. Comm. mol. Pathol. Pharmacol., 85, 347-350
115. Gherman, R.B., Parker, M.F. & Macri, C.I. (1994) Granulosa cell tumor of the ovary associated with antecedent tamoxifen use. Obstetr. Gynecol., 84, 717-719
116. Ghia, M. & Mereto, E. (1989) Induction and promotion of γ-glutamyltranspeptidase-positive foci in the liver of female rats treated with ethinyl estradiol, clomiphene, tamoxifen and their associations. Cancer Lett., 46, 195-202
117. Gibson, L.E., Barakat, R.R., Curtin, J.P., Jones, W.B., Lewis, J.L., Jr & Hoskins, W.J. (1994) Tamoxifen effects on the endometrium: a retrospective comparative study (Abstract no. 837). Proc. ASCO, 13, 263
118. Gill-Sharma, M.K., Gopalkrishnan, K., Balasinor, N., Parte, P., Jayaraman, S. & Juneja, H.S. (1993) Effects of tamoxifen on the fertility of male rats. J. Reprod. Fert., 99, 395-402
119. Gillett, D. (1995) Leiomyosarcoma of the uterus in a woman taking adjuvant tamoxifen therapy (Letter to the Editor). Med. J. Aust., 163, 160-161
120. Glick, J.H., Creech, R.H., Torri, S., Holdroyde, C., Brodovsky, H., Catalano, R.B. & Varano, M. (1981) Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer. Breast Cancer Res. Treat., 1, 59-68
121. Click, J.H., Gelber, R.D., Goldhirsch, A. & Senn, H.-J. (1992) Meeting highlights: adjuvant therapy for primary breast cancer. J. natl Cancer Inst., 84, 1479-1485
122. Goldfarb, S. (1976) Sex hormones and hepatic neoplasia. Cancer Res., 36, 2584-2588
123. Goldhirsch, A., Wood, W.C., Senn, H.-J., Glick, J.H. & Gelber, R.D. (1995) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J. natl Cancer Inst., 87, 1441-1445
124. Goodwin, J.W., Crowley, J., Eyre, H.J., Stafford, B., Jaeckle, K.A. & Townsend, J.J. (1993) A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study. J. Neuro-Oncol., 15, 75-77
125. Gooren, L. (1989) Improvement of spermatogenesis after treatment with the antiestrogen tamoxifen in a man with the incomplete androgen insensitivity syndrome. J. clin. Endocrinol. Metab., 68, 1207-1210
126. Gordon, D., Beastall, G.H., McArdle, C.S. & Thomson, J.A. (1986) The effect of tamoxifen therapy on thyroid function tests. Cancer, 58, 1422-1425
127. Gray, R. (1993) Tamoxifen: how boldly to go where no women have gone before. J. natl Cancer Inst., 85, 1358-1360
128. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. & Orton, T. (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53, 3919-3924
129. Grey, A.B., Stapleton, J.P., Evans, M.C. & Reid, I.R. (1995a) The effects of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J. clin. Endocrinol. Metabol., 80, 3191-3195
130. Grey, A.B., Stapleton, J.P., Evans, M.C., Tatnell, M.A., Ames, R.W. & Reid, I.R. (1995b) The effects of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am. J. Med., 99, 636-641
131. Griffiths, M.F.P. (1987) Tamoxifen retinopathy at low dosage (Letter to the Editor). Am. J. Ophthalmol., 104, 185-186
132. Guelen, P.J.M., Stevenson, D., Briggs, R.J. & de Vos, D. (1987) The bioavailability of Tamoplex (tamoxifen). Part 2. A single dose cross-over study in healthy male volunteers. Meth. Find. exp. clin. Pharmacol., 9, 685-690
133. Guetta, V., Lush, R.M., Figg, W.D., Waclawiw, M.A. & Cannon, R.O., III (1995) Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in post-menopausal women. Amer. J. Cardiol., 76, 1072-1073
134. Gulino, A., Screpanti, I. & Pasqualini, J.R. (1984) Differential estrogen and antiestrogen responsiveness of the uterus during development in the fetal, neonatal and immature guinea pig. Biol. Reprod., 31, 371-381
135. Gupta, J.S. & Roy, S.K. (1987) Effect of tamoxifen on cytosolic estrogen receptor in the different parts of fallopian tube and uterus during ovum transport. Exp. clin. Endocrinol., 90, 293-300
136. 8-cholesterol conversion to lathosterol in women with breast cancer. J. clin. Oncol., 13, 2900-2905
137. Han, X. & Liehr, J.G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52, 1360-1363
138. Hard, G.C., Iatropoulos, M.J., Jordan, K., Radi, L., Kaltenberg, O.P., Imondi, A.R. & Williams, G.M (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res., 53, 4534-4541
139. Hardell, L. (1988a) Tamoxifen as risk factor for carcinoma of corpus uteri (Letter to the Editor). Lancet, ii, 563
140. Hardell, L. (1988b) Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri (Letter to the Editor). Lancet, ii, 1432
141. Harper, M.J.K. & Walpole, A.L. (1966) Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature, 212, 87
142. Harper, M.J.K. & Walpole, A.L. (1967a) A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil., 13, 101-119
143. Harper, M.J.K. & Walpole, A.L. (1967b) Mode of action of ICI 46,474 in preventing implantation in rats. J. Endocrinol., 39, 83-92
144. Harrison, J.D., Morris, D.L., Ellis, I.O., Jones, J.A. & Jackson, I. (1989) The effect of tamoxifen and estrogen receptor status on survival in gastric carcinoma. Cancer, 64, 1007-1010
145. Hasmann, M., Rattel, B. & Löser, R. (1994) Preclinical data for droloxifene. Cancer Lett., 84, 101-116
146. Hatch, K.D., Beecham, J.B., Blessing, J.A. & Creasman, W.T. (1991) Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second-line therapy in 105 patients. Cancer, 68, 269-271
147. Hayes, D.F., Van Zyl, J.A., Hacking, A., Goedhals, L., Bezwoda, W.R., Mailliard, J.A., Jones, S.E., Vogel, C.L., Berris, R.F., Shemano, I. & Schoenfelder, J. (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J. clin. Oncol., 13, 2556-2566
148. Hemminki, K., Widlak, P. & Hou, S.-M. (1995) DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis, 16, 1661-1664
149. Hendrick, A. & Subramanian, V.P. (1980) Tamoxifen and thromboembolism (Letter to the Editor). J. Am. med. Assoc., 243, 514-515
150. Hirsimäki, P., Hirsimäki, Y., Nieminen, L. & Payne, B.J. (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: a I-year study with two antiestrogens. Arch. Toxicol., 67, 49-54
151. Hulka, C.A. & Hall, D.A. (1993) Endometrial abnormalities associated with tamoxifen therapy for breast cancer: sonographic and pathologic correlation. Am. J. Roentgentol., 160, 809-812
152. IARC (1987a) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Suppl. 7, Overall Evaluations of Carcinogenicity: An Update of IARC Monographs Volumes 1 to 42, Lyon, pp. 82-83, 182-184, 210-211, 239-240, 241-242
153. IARC (1987b) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Suppl. 7, Overall Evaluations of Carcinogenicity: An Update of IARC Monographs Volumes 1 to 42, Lyon, pp. 272-310
154. Iguchi, T., Hirokawa, M. & Takasugi, N. (1986) Occurrence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen. Toxicology, 42, 1-11
155. Iguchi, T., Irisawa, S., Uchima, F.-D.A. & Takasugi, N. (1988) Permanent chondrification in the pelvis and occurrence of hernias in mice treated neonatally with tamoxifen. Reprod. Toxicol., 2, 127-134
156. Ingle, J.N. (1984) Additive hormonal therapy in women with advanced breast cancer. Cancer, 53, 766-777
157. Ingle, J.N., Ahmann, D.L., Green, S.J., Edmonson, J.H., Bisel, H.F., Kvols, L.K., Nichols, W.C., Creagan, E.T., Hahn, R.G., Rubin, J. & Frytak, S. (1981) Randomized clinical trial of diethyl-stilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. New Engl. J. Med., 304, 16-21
158. Ingle, J.N., Krook, J.E., Green, S.J., Kubista, T.P., Everson, L.K., Ahman, D.L., Chang, M.N., Bisel, H.F., Windschitl, H.E., Twito, D.I. & Pfeifle, D.M. (1986) Randomized trial of bilaterial oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J. clin. Oncol., 4, 178-185
159. Irisawa, S. & Iguchi, T. (1990) Critical period of induction by tamoxifen of genital organ abnormalities in female mice. In Vivo, 4, 175-180
160. Ismail, S.M. (1994) Pathology of endometrium treated with tamoxifen. J. clin. Pathol., 47, 827-833
161. Jaiyesimi, I.A., Buzdar, A.U., Sahin, A.A. & Ross, M.A. (1992) Carcinoma of the male breast. Ann. intern. Med., 117, 771-777
162. Jaiyesimi, I.A., Buzdar, A.U., Decker, D.A. & Hortobagyi, G.N. (1995) Use of tamoxifen for breast cancer : 28 years later. J. clin. Oncol., 13, 513-529
163. 5-ethyl]tamoxifen. Carcinogenesis, 16, 683-688
164. Johnstone, A.J., Sarkar, T.K. & Hussey, J.K. (1991) Primary hepatocellular carcinoma in a patient with breast carcinoma. Clin. Oncol., 3, 180-181
165. Jones, A.L., Powles, T.J., Treleaven, J.G., Burman, J.F., Nicolson, M.C., Chung, H.-I. & Ashley, S.E. (1992) Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Br. J. Cancer, 66, 744-747
166. Jordan, V.C. (1978) Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Rev. Endocrinol. rel. Cancer (October Supplement), 49-55
167. Jordan, V.C. (1988) The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res. Treat., 11, 197-209
168. Jordan, V.C. (1993) A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol, 110, 507-517
169. 3H]tamoxifen in rat uterine cytosols: a comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis. Mol. Cell Endocrinol., 8, 179-188
170. Jordan, V.C. & Robinson, S.P. (1987) Species-specific pharmacology of antiestrogens: role of metabolism. Fed. Proc., 46, 1870-1874
171. Jordan, V.C., Dix, C.J. & Allen, K.E. (1979) The effectiveness of long-term treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Salmon, S.E. & Jones, S.E., eds, Adjuvant Therapy of Cancer, Vol. 2, New York, Grune and Stratton, pp. 19-26
172. Jordan, V.C., Allen, K.E. & Dix, C.J. (1980) Pharmacology of tamoxifen in laboratory animals. Cancer Treat. Rep., 64, 745-759
173. Jordan, V.C., Fritz, N.F. & Tormey, D.C. (1987) Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res., 57, 4517-4519
174. Jordan, V.C., Lababidi, M.K. & Mirecki, D.M. (1990) Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. Eur. J. Cancer, 26, 718-721
175. Jordan, V.C., Lababidi, M.K. & Langan-Fahey, S. (1991) Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J. natl Cancer Inst., 83, 492-496
176. Jose, R., Kekre, A.N., Geoge, S.s. & Seshadri, L. (1995) Endometrial carcinoma in a tamoxifen-treated breast cancer patient. Aust. N.Z. J. Obstet. Gynaecol., 35, 201
177. Kaiser-Kupfer, M.I. & Lippman, M.E. (1978) Tamoxifen retinopathy. Cancer Treat. Rep., 62 315-320
178. Kangas, L., Nieminen, A.-L., Blanco, G., Grönroos, M., Kallio, S., Karjalainen, A., Perilä, M., Södervall, M. & Toivola, R. (1986) A new triphenylethylene compound, Fc-1157a. II. Anti-tumor effects. Cancer Chemother. Pharmacol., 17, 109-113
179. Kawamura, I., Mizota, T., Kondo, N., Shimomura, K. & Kohsaka, M. (1991) Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Jpn. J. Pharmacol., 57, 215-224
180. Kedar, R.P., Bourne, T.H., Powles, T.J., Collins, W.P., Ashley, S.E., Cosgrove, D.O. & Campbell, S. (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet, 343, 1318-1321
181. Kenny, A.M., Prestwood, K.M., Pilbeam, C.C. & Raisz, L.G. (1995) The short term effects of tamoxifen on bone turnover in older women. J. Clin. Endocrinol. Metabol., 80, 3287-3291
182. Killackey, M.A., Hakes, T.B. & Pierce, V.K. (1985) Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rep., 69, 237-238
183. Kitaichi, M., Nishimura, K., Itoh, H. & Izumi, T. (1995) Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am. J. respir. crit. Care Med., 151, 527-533
184. Knabbe, C., Lippman, M.E., Wakefield, L.M., Flanders, K.C., Kasid, A., Derynck, R. & Dickson, R.B. (1987) Evidence that TGF-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell, 48, 417-428
185. Kohigashi, K., Fukuda, Y. & Imura, H. (1988) Inhibitory effect of tamoxifen on diethylstilbestrol-promoted hepatic tumorigenesis in male rats and its possible mechanism of action. Jpn. J. Cancer Res. (Gann), 79, 1335-1339
186. Korach, K.S., Fox-Davies, C., Quarmby, V.E. & Swaisgood, M.H. (1985) Diethylstilbestrol metabolites and analogs. Biochemical probes for differential stimulation of uterine estrogen responses. J. biol. Chem., 260, 15420-15426
187. Korach, K.S., Horigome, T., Tomooka, Y., Yamashita, S., Newbold, R.R. & McLachlan, J.A. (1988) Immunodetection of estrogen receptor in epithelial and stromal tissues of neonatal mouse uterus. Proc. natl Acad. Sci., 85, 3334-3337
188. Kotoulas, I.-G., Mitropoulos, D., Cardamakis, E., Dounis, A. & Michopoulos, J. (1994) Tamoxifen treatment in male infertility. I. Effect on spermatozoa. Fert. Ster., 61, 911-914
189. Krause, A. & Gerber, B. (1994) Postmenopausal hemorrhage and endometrial carcinoma during tamoxifen therapy. Zbl. Gynakol., 116, 44-47 (in German)
190. Krause, W., Holland-Moritz, H. & Schramm, P. (1992) Treatment of idiopathic oligozoospermia with tamoxifen - a randomized controlled study. Int. J. Androl., 15, 14-18
191. Kristensen, B., Ejlersten, B., Dalgaard, P., Larsen, L., Nistrup Holmegaard, S., Transbøl, I. & Mouridsen, H.T. (1994) Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J. Clin. Oncol., 12, 992-997
192. Lahti, E., Blanco, G., Kauppila, A., Apaja-Sarkkinen, M., Taskinen, P.J. & Laatikainen, T. (1993) Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet. Gynecol., 81, 660-664
193. Lai, C.-H., Hsueh, S., Chao, A.-S. & Soong, Y.-K. (1994) Successful pregnancy after tamoxifen and megestrol acetate therapy for endometrial carcinoma. Br. J. Obstet. Gynaecol., 101, 547-549
194. Lang-Avérous, G., Rupp, K., Wehner, H. & Dallenbach-Hellweg, G. (1991) The role of steroid hormones and related biological substances in the etiology of endometrial carcinoma. Verh. Dtsch. ges. Pathol., 75, 366-369 (in German)
195. Lanza, A., Alba, E., Re, A., Tessarolo, M., Leo, Bellino, R., Lauricella, A. & Wierdis, T. (1994) Endometrial carcinoma in breast cancer patients treated with tamoxifen. Two case reports and review of the literature. Eur. J. Gynaec. Oncol., 15, 455-459
196. Le Bouëdec, G. & Dauplat, J. (1992) Cancer of the endometrium caused by antiestrogens. Rev. Fr. Gynécol. Obstét., 87, 345-348 (in French)
197. Le Bouëdec, G., De Latour, M., Feillel, V. & Dauplat, J. (1990) Metrorrhagia and tamoxifen. 22 patients treated for breast cancer. J. Gynécol. Obstét. Biol. Reprod., 19, 889-894 (in French)
198. Le Bouëdec, G., Kauffmann, P., De Latour, M., Fondrinier, E., Curé, H. & Dauplat, J. (1991) Metastases of cancer of the breast in the uterus. 8 case histories. J. Gynécol. Obstét. Biol. Reprod., 20, 349-354 (in French)
199. van Leeuwen, F.E., Benraadt, J., Coebergh, J.W.W., Kiemeney, L.A.L.M., Gimbrère, C.H.F., Otter, R., Schouten, L.J., Damhuis, R.A.M., Bontenbal, M., Diepenhorst, F.W., van den Belt-Dusebout, A.W. & van Tinteren, H. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet, 343, 448-452
200. Le Roy, X., Escot, C., Brouillet, J.-P., Theillet, C., Maudelonde, T., Simony-Lafontaine, J., Pujol, H. & Rochefort, H. (1991) Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. Oncogene, 6, 431-437
201. Lentz, S.S. (1994) Advanced and recurrent endometrial carcinoma: hormonal therapy. Sem. Oncol., 21, 100-106
202. Leo, L., Lanza, A., Re, A., Tessarolo, M., Bellino, R., Lauricella, A. & Wierdis, T. (1994) Leiomyomas in patients receiving Tamoxifen. Clin. exp. Obstet. Gynecol., 21, 94-98
203. Leslie, W.D., Cowden, E.A. & MacLean, J.P. (1995) Oestrogen and bone density: a comparison of tamoxifen and hypo-oestrogenaemia. Nuclear Med. Commun., 16, 698-702
204. Liehr, J.G., Sirbasku, D.A., Jurka, E., Randerath, K. & Randerath, E. (1988) Inhibition of estrogen-induced renal carcinogenesis in male Syrian hamsters by tamoxifen without decrease in DNA adduct levels. Cancer Res., 48, 779-783
205. Lien, E.A., Solheim, E., Lea, O.A., Lundgren, S., Kvinnsland, S. & Ueland P.M. (1989) Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res., 49, 2175-2183
206. Lien, E.A., Solheim, E. & Ueland, P.M. (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res., 51, 4837-4844
207. Lien, E.A., Anker, G. & Ueland, P.M. (1995) Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer. J. Steroid Biochem. mol. Biol., 55, 229-231
208. Lim, C.K., Chow, L.C.L., Yuan, Z.-X. & Smith, L.L. (1993) High performance liquid chromatography of tamoxifen and metabolites in plasma and tissues. Biomed. Chromatogr., 7, 311-314
209. Lim, C.K., Yuan, Z.-X., Lamb, J.H., White, I.N.H., De Matteis, F. & Smith, L.L. (1994) A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis, 15, 589-593
210. Lin, C.L. & Buttle, H.L. (1990) Progesterone receptor in the mammary tissue of pregnant and lactating gilts and the effect of tamoxifen treatment during late gestation. J. Endocrinol., 130, 251-257
211. Lin, C.L. & Buttle, H.L. (1991) Effect of oestradiol benzoate and tamoxifen on the growth of and induction of progesterone receptors in the uterus and mammary gland of immature pigs. J. Endocrinol., 130, 259-265
212. Lipton, A., Harvey, H.A. & Hamilton, R.W. (1984) Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat. Rep., 68, 887-889
213. LiVolsi, V.A., Salhany, K.E. & Dowdy, Y.G. (1995) Endocervical adenocarcinoma in tamoxifen-treated patient (Letter to the Editor). Am. J. Obstet. Gynecol., 172, 1065
214. Longstaff, S., Sigurdsson, H., O'Keefe, M., Ogston, S. & Preece, P. (1989) A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur. J. Cancer clin. Oncol., 25, 1805-1808
215. Love, R. (1989) Tamoxifen therapy in primary breast cancer: biology, efficacy and side effects. J. clin. Oncol., 7, 803-815
216. Love, R.R. & Feyzi, J.M. (1993) Reduction in vasomotor symptoms from tamoxifen over time. J. natl Cancer Inst., 85, 673-674
217. Love, R.R., Mazess, R.B., Tormey, D.C., Barden, H.S., Newcomb, P.A. & Jordan, V.C. (1988) Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res. Treat., 12, 297-302
218. Love, R.R., Newcomb, P.A., Wiebe, D.A., Surawicz, T.S., Jordan, V.C., Carbone, P.P. & DeMets, D.L. (1990) Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J. natl Cancer Inst., 82, 1327-1332
219. Love, R.R., Wiebe, D.A., Newcomb, P.A., Cameron, L., Leventhal, H., Jordan, V.C., Feyzi, J. & DeMets, D.L. (1991) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. intern. Med., 115, 860-864
220. Love, R.R., Surawicz, T.S. & Williams, E.G. (1992a) Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch. intern. Med., 152, 317-320
221. Love, R.R., Mazess, R.B., Barden, H.S., Epstein, S., Newcombe, P.A., Jordan, V.C., Carbone, P.P. & DeMets, D.L. (1992b) Effect of tamoxifen on bone mineral density in post-menopausal women with breast cancer. New Engl. J. Med., 326, 852-856
222. Love, R.R., Wiebe, D.A., Feyzi, J.M., Newcombe, P.A. & Chappell, R.J. (1994a) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J natl Cancer Inst., 86, 1534-1539
223. Love, R.R., Barden, H.S., Mazess, R.B., Epstein, S. & Chappell, R.J. (1994b) Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch. intern. Med., 154, 2585-2588
224. Lüllmann, H. & Lullmann-Rauch, R. (1981) Tamoxifen-induced generalised lipidosis in rats subchronically treated with high doses. Toxicol. appl. Pharmacol., 61, 138-146
225. Lumsden, M.A., West, C.P. & Baird, D.T. (1989) Tamoxifen prolongs luteal phase in premenopausal women but has no effect on the size of uterïne fibroids. Clin. Endocrinol., 31, 335-343
226. Mäentausta, O., Svalander, P., Danielsson, K.G., Bygdeman, M. & Vihko, R. (1993) The effects of an antiprogestin, mifepristone, and an antiestrogen, tamoxifen, on endometrial 17β-hydroxysteroid dehydrogenase and progestin and estrogen receptors during the luteal phase of the menstrual cycle: an immunohistochemical study. J. clin. Endocrinol. Metab., 77, 913-918
227. Magriples, U., Naftolin, F., Schwartz, P.E. & Carcangiu, M.L. (1993) High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. clin. Oncol., 11, 485-490
228. Malfetano, J.H. (1990) Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol. Oncol., 39, 82-84
229. Mamby, C.C., Love, R.R. & Lee, K.E. (1995) Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J. clin. Oncol., 13, 854-857
230. Mani, C. & Kupfer, D. (1991) Cytochrome P-450-mediated activation and irreversible binding of the antioestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing mono-oxygenases in tamoxifen activation. Cancer Res., 51, 6052-6058
231. Mani, C., Gelboin, H.V., Park, S.S., Pearce, R., Parkinson, A. & Kupfer D. (1993) Metabolism of the antimammary cancer antioestrogenic agent tamoxifen 1. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos., 21, 645-656
232. Mani, C., Pearce, R., Parkinson, A. & Kupfer D. (1994) Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis, 15, 2715-2720
233. Manni, .A., Trujillo, J.E., Marshall, J.S., Brodkey, J. & Pearson, O.H. (1979) Antihormone treatment of stage IV breast cancer. Cancer, 43, 444-450
234. Mäntylä, E.T.E., Nieminen, L.S. & Karlsson, S.H. (1995) Endometrial cancer induction by tamoxifen in the rat (Abstract no. 61). Eur. J. Cancer, 31A (Suppl. 5), S14
235. Mäntylä, E.T.E., Karlsson, S.H. & Nieminen, L.S. (1996) Induction of endometrial cancer by tamoxifen in the rat. In: Li, J.J., Li, S.A., Gustafsson, J.-Å., Nandi, S. & Sekely, L.I., eds., Hormonal Carcinogenesis. II. Proceedings of the Second International Symposium, New York, Springer Verlag, pp. 442-445
236. Marshall, K. & Senior, J. (1987) A study on the effect of a single dose of tamoxifen on uterine hyperaemia and growth in the rat. Br. J. Pharmacol., 92, 429-435
237. Martin, L. (1980) Estrogens, anti-estrogens and the regulation of cell proliferation in the female reproductive tract in vivo. In: McLachlan, J.A., Korach, K. & Lamb, J.C., eds, Estrogens in the Environment, New York, Elsevier/North Holland, pp. 103-129
238. Martin, E.A., Rich, K.J., White, I.N.H., Woods, K.L., Powles, T.J. & Smith, L.L. (1995) "P-Postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis, 16, 1651-1654
239. Martínez Cerezo, F.J., Tomás, A., Donoso, L., Enríquez, J., Guarner, C., Balanzó, J., Martínez Nogueras, A. & Vilardell, F. (1994) Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J. Hepatol., 20, 702-706
240. Mastri, C., Mistry, P. & Lucier, G.W. (1985) In vivo oestrogenicity and binding characteristics of alpha-zearalanol (P-1496) to different classes of oestrogen binding proteins in rat liver. J. Steroid Biochem., 23, 279-289
241. Mathew, A., Chabon, A.B., Kabakow, B., Drucker, M. & Hirschman, R.J. (1990) Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. N.Y. State J. Med., 90, 207-208
242. McAuliffe, F.M. & Foley, M.E. (1993) Tamoxifen and endometrial lesions (Letter to the Editor). Lancet, 342, 1124
243. McClay, E.F. & McClay, M.E.T. (1994) Tamoxifen: is it useful in the treatment of patients with metastatic melanoma ?. clin. Oncol., 12, 617-626
244. McClay, E.F., Albright, K.D., Jones, J.A., Christen, R.D. & Howell, S.B. (1993) Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int. J. Cancer, 55, 1018-1022
245. McClellan, M.C., West, N.B., Tacha, D.E., Greene, G.L. & Brenner, R.M. (1984) Immunocytochemical localization of estrogen receptors in the macaque reproductive tract with monoclonal antiestrophilins. Endocrinol., 114, 2002-2014
246. McDermott, M.T., Hofeldt, F.D. & Kidd, G.S. (1990) Tamoxifen therapy for painful idiopathic gynecomastia. South. med. J., 83, 1283-1285
247. McDonald, C.C. & Stewart, H.J. (1991) Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br. med. J., 303, 435-437
248. McDonald, C.C., Alexander, F.E., Whyte, B.W., Forrest, A.P. & Stewart, H.J. (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. Br. med. J., 311, 977-980
249. McVie, J.G., Simonetti, G.P.C., Stevenson, D., Briggs, R.J., Guelen, P.J.M. & de Vos, D. (1986) The bioavailability of Tamoplex (tamoxifen). Part 1. A pilot study. Meth. Find. exp. clin. Pharmacol., 8, 505-512
250. Medical Economics (1996) PDR®: Physicians' Desk Reference, 50th Ed., Montvale, NJ, Medical Economics Data Production Co., pp. 2842-2844
251. Metzler, M. & Schiffmann, D. (1991) Structural requirements for the in vitro transformation of Syrian hamster embryo cells by stilbene estrogens and triphenylethylene-type antiestrogens. Am. J. clin. Oncol., 14 (Suppl. 2), S30-S35
252. Mignotte, H., Sasco, A.J., Lasset, C., Saez, S. & Rivoire, M. (1992) Adjuvant therapy of breast cancer with tamoxifen and endometrial carcinoma. Bull. Cancer, 79, 969-977 (in French)
253. Mike, V., Currie, V.E. & Gee, T.S. (1994) Fatal neutropenia associated with long-term tamoxifen therapy. Lancet, 344, 541-542
254. Mishkin, S.Y., Farber, E., Ho, R., Mulay, S. & Mishkin, S. (1985) Tamoxifen alone or in combination with estradiol-17β inhibits the growth and malignant transformation of hepatic hyperplastic nodules. Eur. J. Cancer clin. Oncol., 21, 615-623
255. Montandon, F. & Williams, G.M. (1994) Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Arch. Toxicol., 68, 272-275
256. Moon, L.Y., Wakley, G.K. & Turner, R.T. (1991) Dose-dependent effects of tamoxifen on long bones in growing rats: influence of ovarian status. Endocrinology, 129, 1568-1574
257. Moon, R.C., Steele, V.E., Kelloff, G.J., Thomas, C.F., Detrisac, C.J., Mehta, R.G. & Lubet, R.A. (1994) Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. Anticancer Res., 14, 889-894
258. Moorthy, B., Sriram, P., Pathak, D.N., Bodell, W.J. & Randerath, K. (1996) Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res., 56, 53-57
259. Mouridsen, H.T., Rose, C., Overgaard, M., Dombernowsky, P., Panduro, J., Thorpe, S., Rasmussen, B.B., Blichert-Toft, M. & Andersen, K.W. (1988) Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Acta oncol., 27, 699-705
260. Mühlemann, K., Cook, L.S. & Weiss, N.S. (1994) The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977. Breast Cancer Res. Treat., 30, 201-204
261. Murphy, C., Fotsis, T., Pantzer, P., Aldercreutz, H. & Martin, F. (1987) Analysis of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KCl-nuclear extracts of breast tumours from tamoxifen treated patients by gas chromatography-mass spectometry (GC-MS) using selected ion monitoring (SIM). J. Steroid Biochem., 28, 609-618
262. Muss, H.B. (1992) Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res. Treat., 21, 15-26
263. Mustacchi, G., Milani, S., Pluchinotta, A., De Matteis, A., Rubagotti, A. & Perrota, A. (1994) Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer. The G.R.E.T.A. (Group for Research on Endocrine Therapy in the Elderly) Trial. Anticancer Res:, 14, 2197-2200
264. National Institutes of Health Consensus Development Panel (1992) Consensus statement: treatment of early-stage breast cancer. J. natl Cancer Inst., 11, 1-5
265. National Surgical Adjuvant Breast and Bowel Project (1992) NSABP Protocol P-1: A Clinical Trial to Determine the Worth of Tamoxifen for Preventing Breast Cancer, Pittsburgh, PA, University of Pittsburgh, January 24
266. Nayfield, S.G., Karp, I.E., Ford, L.G., Dorr, F.A. & Kramer, B.S. (1991) Potential role of tamoxifen in prevention of breast cancer. J. natl Cancer Inst., 83, 1450-1459
267. Nevasaari, K., Heikkinen, M. & Taskinen, P.J. (1978) Tamoxifen and thrombosis. Lancet., ii, 946-947
268. Neven, P., De Muylder, X., Van Belle, Y., Vanderick, G. & De Muylder, E. (1989) Tamoxifen and the uterus and endometrium (Letter to the Editor). Lancet, i, 375
269. Neven, P., De Muylder, X., Van Belle, Y., Vanderick, G. & De Muylder, E. (1990) Hysteroscopic follow-up during tamoxifen treatment. Eur. J. Obstet. Gynecol. reprod. Biol., 35, 235-238
270. Noguchi, M., Taniya, T., Tarjiri, K., Miwa, K., Miyazaki, I., Koshino, H., Mabuchi, H. & Nomomura, A. (1987) Fatal hyperlipaemia in a case of metastatic breast cancer treated by tamoxifen, Br. J. Surg., 74, 586-587
271. Nolvadex Adjuvant Trial Organisation (NATO) (1983) Controlled trial of tamoxifen as adjuvant agent in the management of early breast cancer. Interim analysis at four years. Lancet, i, 257-261
272. Nolvadex Adjuvant Trial Organisation (NATO) (1988) Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br. J. Cancer, 57, 608-611
273. Nuovo, M.A., Nuovo, G.J., McCaffrey, R.M., Levine, R.U., Barron, B. & Winkler, B. (1989) Endometrial polyps in postmenopausal patients receiving tamoxifen. Int. J. gynecol. Pathol., 8, 125-131
274. Nuwaysir, E.F., Dragan, Y.P., Jefcoate, C.R,. Jordan, V.C. & Pitot, H.C. (1995) Effects of tamoxifen administration on the expression of xenobiotic metabolising enzymes in rat liver. Cancer Res., 55, 1780-1786
275. O'Dea, J.P.K. & Davis, E.H. (1990) Tamoxifen in the treatment of menstrual migraine. Neurology, 40, 1470-1471
276. O'Grady, J.E., Armstrong, E.M., Moore, I.A.R. & Vass, M.A. (1974) Effect of tamoxifen (ICI-46,474) on mitosis in the uterus of the rat during the early stages of pregnancy. J. Endocrinol., 63, 19P
277. O'Halloran, M.J. & Maddock, P.G. (1974) ICI 46,474 in breast cancer. J. Irish med. Assoc., 67, 38-39
278. Ohta, Y., Iguchi, T. & Takasugi, N. (1989) Deciduoma formation in rats treated neonatally with the anti-estrogens, tamoxifen and MER-25. Reprod. Toxicol., 3, 207-212
279. Olive, D.L., Groff, T.R., Schultz, N., Schenken, R.S. & Riehl, R.M. (1990) Effects of tamoxifen on corpus luteum function and luteal phase length in cynomolgus monkeys. Fert. Ster., 54, 333-338
280. O'Neill, E. & Rodríguez Mojica, W. (1992) Asymptomatic carcinoma of the endometrium in a patient on adjunctive tamoxifen therapy for carcinoma of the breast. Bol. Asoc. Med P.R., 84, 74-77
281. Oredipe, O.A., Barth, R.F., Dwivedi, C. & Webb, T.E. (1992) Dietary glucarate-mediated inhibition of initiation of diethylnitrosamine-induced hepatocarcinogenesis. Toxicology, 74, 209-222
282. Osborne, M.R., Hewer, A., Hardcastle, I.R., Carmichael, P.L. & Phillips, D.H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56, 66-71
283. Palacios, A., Pertusa, S., Montoya, A. & Martínez San Pedro, R. (1993) Breast cancer, tamoxifen, and uterus (Letter to the Editor). Med. clin. Bare., 100, 479 (in Spanish)
284. Palshof, T. (1988) Adjuvant Endocrine Therapy in Premenopausal and Postmenopamal Women with Breast Cancer. Report of the Copenhagen Breast Cancer Trials 1975-1987, Thesis, Copenhagen, Medi-book
285. Parry, B.R., Hung, N.A., McCall, J.L. & Phipps, R.F. (1993) Apparent regression of rectal polyps in a patient with Gardner's syndrome receiving concomitant tamoxifen therapy. Aust. N.Z. J. Surg., 63, 578-579
286. Pasqualini, J.R. & Lecerf, F. (1986) Ultrastructural modifications provoked by tamoxifen either alone or combined with oestradiol in the uteri of fetal or newborn guinea-pigs. J. Endocrinol., 110, 197-202
287. Pasqualini, J.R., Nguyen, B.-L., Sumida, C., Giambiagi, N. & Mayrand, C. (1986) Tamoxifen and progesterone effects in target tissues during the perinatal period. J. Steroid Biochem., 25, 853-857
288. Pasqualini, J.R., Sumida, C., Giambiagi, N.A. & Nguyen, B.L. (1987) The complexity of antioestrogen responses. J. Steroid. Biochem., 27, 883-889
289. Pathak, D.N. & Bodell, W.J. (1994) DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis, 15, 529-532
290. Pathak, D.N., Pongracz, K. & Bodell, W.J. (1995) Microsomal and peroxidase activation of 4-hydroxytamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis, 16, 11-15
291. Pavlidis, N., Petris, C., Briassoulis, E., Klouvas, G., Psilas, C., Rempapis, J. & Petroutsos, G. (1992) Clear evidence that long-term, low dose tamoxifen treatment can induce ocular toxicity. Cancer, 69, 2961-2964
292. Perry, R.R., Kang, Y. & Greaves, B. (1985) Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann. surg. Oncol., 2, 238-245
293. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.J. & Poon, G.K. (1994a) α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res., 54, 5518-5522
294. 5-ethyl]tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis, 15, 1487-1492
295. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.J., Hardcastle, I.R., Poon, G.K., Keogh, A. & Strain, A.J. (1996a) Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis, 17, 89-94
296. Phillips, D.H., Hewer, A., Grover, P.L., Poon, G.K. & Carmichael, P.L. (1996b) Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. Carcinogenesis, 17, 1149-1152
297. Planting, A.S.T., Alexieva-Figusch, J., Blonk-v.d.Wijst, J. & van Putten, W.L.J. (1985) Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer Treat. Rep., 69, 363-368
298. Pongracz, K., Pathak, D.N., Nakamura, T., Burlingame, A.L. & Bodell, W.J. (1995) Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res., 55, 3012-3015
299. Pons, J.Y. & Rigonnot, L. (1988) Hyperplasia of the endometrium in menopausal patients treated with tamoxifen for a breast cancer. J. Gynecol. Obstet. Biol. reprod., 17, 11-20 (in French)
300. Poon, G.K., Chui, Y.C., McCague, R., Lønning, P.E., Feng, R., Rowlands, M.G. & Jarman, M. (1993) Analysis of Phase I and Phase II metabolites of tamoxifen in breast cancer patients. Drug Metab. Disp., 21, 1119-1124
301. Poon, G.K., Walter, B., Lønning, P.E., Horton, M.N. & McCague, R. (1995) Identification of tamoxifen metabolites in human HEP G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab. Disp., 23, 377-382
302. Potter, G.A., McCague, R. & Jarman, M. (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis, 15, 439-442
303. Powles, T.J., Tillyer, C.R., Jones, A.L., Ashley, S.E., Treleaven, J., Davey, J.B. & McKinna, J.A. (1990) Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital pilot programme. Eur. J. Cancer, 26, 680-684
304. Poyser, N.L. (1993) Effects of onapristone, tamoxifen and ICI 182780 on uterine prostaglandin production and luteal function in nonpregnant guinea-pigs. J. Reprod. Fert., 98, 307-312
305. Pritchard, K.I., Thomson, D.B., Myers, R.E., Sutherland, D.J.A., Mobbs, B.C. & Meakin, J.W. (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat. Rep., 64, 787-796
306. Pritchard, K.I., Meakin, J.W., Boyd, N.F., DeBoer, G., Paterson, A.H.G., Ambus, U., Dembo, A.J., Sutherland, D.J.A., Wilkinson, R.H., Bassett, A.A., Evans, W.K., Beale, F.A., Clark, R.M. & Keane, T.J. (1987) Adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer: an update. In: Salmon, S.E. & Jones, S.E., eds, Adjuvant Therapy of Cancer, New York, Grune & Stratton, pp. 391-400
307. Pugh, D.M. & Sumano, H.S. (1979) The effects of oestradiol-17β and tamoxifen on the development of mouse embryos cultured over collagen. Br. J. Pharmocol., 67, 458
308. Qinn, M.A. & Campbell, J.J. (1989) Tamoxifen therapy in advanced/recurrent endometrial carcinoma. Gynecol Oncol., 32, 1-3
309. Ralph, D.J., Brooks, M.D., Bottazzo, G.F. & Pryor, J.P. (1992) The treatment of Peyronie's disease with tamoxifen. Br. J. Urol., 70, 648-651
310. Randerath, K., Bi, J., Mabon, N., Sriram, P. & Moorthy, B. (1994a) Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis, 15, 797-800
311. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis, 15, 2087-2094
312. Rasmussen, K.L. & Nielsen, K.M. (1991) Development of endometrial cancer during tamoxifen therapy. Ugeskr. Laeger., 153, 2638 (in Danish)
313. Rayter, Z., Shepherd, J., Gazet, J.-C., Trott, P., Svensson, W. & A'Hern, R. (1993) Tamoxifen and endometrial lesions. Lancet., 342, 1124
314. Redmond, C.K., Wickerham, D.L., Cronin, W., Fisher, B., Costantino, J. & NSABP Participants (1993) The NSABP Breast Cancer Prevention Trial (BCPT): a progress report (Abstract no. 78). Proc. Am. Soc. clin. Oncol., 12, 69
315. Reynolds, J.E.F., ed. (1993) Martindale: The Extra Pharmacopoeia, 30th Ed., London, The Pharmaceutical Press, pp. 500-502
316. Ribeiro, G. & Swindell, R. (1985) The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma: 7-yr results, Eur. J. Cancer clin. Oncol., 21, 897-900
317. Ribeiro, G. & Swindell, R. (1992) The Christie Hospital adjuvant tamoxifen trial. J natl Cancer Inst. Monogr., 11, 121-125
318. Rivkin, S.E., Green, S., Metch, B., Cruz, A.B., Abeloff, M.D., Jewell, W.R., Costanzi, J.J., Farrar, W.B., Minton, J.P. & Osborn, C. K. (1994) Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. 7. clin. Oncol., 12, 2078-2085
319. Robinson, S.P., Mauel, D.A. & Jordan, V.C. (1988) Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. Eur. J. Cancer clin. Oncol., 24, 1817-1821
320. Robinson, S.P., Langan-Fahey, S.M., Johnson, D.A. & Jordan, V.C. (1991) Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab. Dispos., 19, 36-43
321. Robinson, D.C., Bloss, J.D. & Schiano, M.A. (1995) A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol. Oncol., 59, 186-190
322. Rodler, J.F., Camus, E., Janser, J.C., Renaud, R. & Rodier, D. (1990) Tamoxifen and endometrial adenocarcinoma. Bull. Cancer, 77, 1207-1210 (in French)
323. Ruenitz, P.C. & Nanavati, N.T. (1990) Identification and distribution in the rat of acidic metabolites of tamoxifen. Drug Metab. Dispos., 18, 645-648
324. Rutqvist, L.E. (1993) Long-term toxicity of tamoxifen. Recent Results Cancer Res., 127, 257-266
325. Rutqvist, L.E. & Mattsson (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J. natl Cancer Inst., 85, 1398-1406
326. Rutqvist, L.E., Cedermark, B., Glas, U., Johansson, H., Rotstein, S., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J., Hjalmar, M.-L., Ringborg, U. & Participating Members of the Stockholm Breast Cancer Study Group (1992) Randomized trial of adjuvant tamoxifen in node negative postmenopausal breast cancer. Acta oncol., 31, 265-270
327. Rutqvist, L.E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T. & Wilking, N., for the Stockholm Breast Cancer Study Group (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. natl Cancer Inst., 87, 645-651
328. Rydén, S., Fernö, M., Möller, T., Aspegren, K., Bergljung, L., Killander, D. & Landberg, T. (1992) Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta oncol., 31, 271-274
329. Salata, I., Kowalski, J., Czechowski, B., Ochedalski, T., Karowicz, A. & Kowalska-Koprek, U. (1993) Does treatment with antioestrogens in men with oligozoospermia influence the pregnancy course in women after artificial insemination by husband. Gin. Pol., 64, 493-497 (in Polish)
330. Samelis, S.F., Stathopoulos, G.P., Malamos, N.A., Kondili, E., Moschopoulos, N.P. & Papacostas, P. (1992) Toxicity of long-term treatment with tamoxifen in breast cancer patients (Abstract no. 300). Ann. Oncol., 3 (Suppl. 5), 78
331. Sargent, L.M., Dragan, Y.P., Bahnub, N., Wiley, J.E., Sattler, C.A., Schroeder, P., Sattler, G. L., Jordan, V.C. & Pitot, H.C. (1994) Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res., 54, 3357-3360
332. Sasco, A.J., Raffi, F., Satgé, D., Goburdhun, J., Fallouh, B. & Leduc, B. (1995) Endometrial Müllerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer. Int. J. gynecol. Obstet., 48, 307-310
333. Sasco, A.J., Chaplain, G., Amoros, E. & Saez, S. (1996) Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology, 7, 9-13
334. Sawka, C.A., Pritchard, K.I., Paterson, A.H.G., Sutherland, D.J.A., Thomson, D.B., Shelley, W.E., Myers, R.E., Mobbs, B.C., Malkin, A. & Meakin, J.W. (1986) Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res., 46, 3152-3156
335. Segna, R.A., Dottino, P.R., Deligdisch, L. & Cohen, C.J. (1992) Tamoxifen and endometrial cancer. Mt Sinai. J. Med., 59, 416-418
336. Sengupta, A., Dutta, S. & Mallick, R. (1991) Modulation of cervical carcinogenesis by tamoxifen in a mouse model system. Oncology, 48, 258-261
337. Seoud, M.A.-F., Johnson, J. & Weed, J.C., Jr (1993) Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet. Gynecol., 82, 165-169
338. Servais, P. & Galand, P. (1993) Increased yield in GST-P-positive liver pre-neoplastic foci induced by DENA or ENU in rats pre-treated with estradiol or tamoxifen. Int. J. Cancer, 54 996-1001
339. Shewmon, D.A., Stock, J.L., Abusamra, L.C., Kristan, M.A., Baker, S. & Heiniluoma, K.M. (1994) Tamoxifen decreases lipoprotein (a) in patients with breast cancer. Metabolism, 43, 531-532
340. Silva, E.G., Tornos, C.S. & Follen-Mitchell, M. (1994) Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int. J. gynecol. Pathol., 13, 248-258
341. Sonnendecker, H.E.M., Cooper, K. & Kalian, K.N. (1994) Case report. Primary Fallopian tube adenocarcinoma in situ associated with adjuvant tamoxifen therapy for breast carcinoma. Gynecol. Oncol., 52, 402-407
342. Spinelli, G., Bardazzi, N., Citernesi, A., Fontanarosa, M. & Curiel, P. (1991) Endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Chemother., 3, 267-270
343. Stephens, C.J.M., Wojnarowska, F.T. & Wilkinson, J.D. (1989) Autoimmune progesterone dermatitis responding to tamoxifen. Br. J. Dermatol., 121, 135-137
344. Sterzik, K., Rosenbusch, B., Mogck, J., Heyden, M. & Lichtenberger, K. (1993) Tamoxifen treatment of oligozoospermia: a reevaluation of its effects including additional sperm function tests. Arch. Gynecol. Obstet., 252, 143-147
345. Stewart, H.J. (for the Scottish Cancer Trials Breast Group) (1992) The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Monogr. natl Cancer Inst., 11, 117-120
346. Stewart, H.J. & Knight, G.M. (1989) Tamoxifen and the uterus and endometrium (Letter to the Editor). Lancet, i, 375-376
347. Styles, J.A., Davies, A., Lim, C.K., De Matteis, F., Stanley, L.A., White, I.N.H., Yuan, Z.-X. & Smith, L.L. (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis, 15, 5-9
348. Sunderland, M.C. & Osborne, C.K. (1991) Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J. clin. Oncol., 9, 1283-1297
349. Swahn, M.I., Bygdeman, M., Matlin, S.A. & Wu, Z.Y. (1989) The effect of tamoxifen on the function and lifespan of the corpus luteum and on subsequent ovarian function. Acta endocrinol., 121, 417-425
350. Swenerton, K.D., Chrumka, K., Paterson, A.H.G. & Jackson, G.C. (1984) Efficacy of tamoxifen in endometrial cancer. In: Bresciani, ed., Progress in Cancer Research and Therapy, Vol. 31, New York, Raven, pp. 417-424
351. Sydow, G. & Wunderlich, V. (1994) Effects of tamoxifen, droloxifene and 17β-estradiol on Rauscher mouse leukemogenesis. Cancer Lett., 82, 89-94
352. Taguchi, O. (1987) Reproductive tract lesions in male mice treated neonatally with tamoxifen. Biol. Reprod., 37, 113-116
353. Tarantal, A.F., Hendrickx, A.C., Matlin, S.A., Lasley, B.L., Gu, Q.-Q., Thomas, C.A.A., Vince, P.M. & van Look, P.F.A. (1993) Tamoxifen as an antifertility agent in the long-tailed macaque. Contraception, 47, 307-316
354. Taylor, O.M., Benson, E.A., McMahon, M.J. & the Yorkshire Gastrointestinal Tumour Group (1993) Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. Br. J. Surg., 80, 384-386
355. Thangaraju, M., Kumar, K., Gandhirajan, R. & Sachdanandam, P. (1994) Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer, 73, 659-663
356. Thomas, J., ed. (1991) Prescription Products Guide 1991, 20th Ed., Victoria, Australian Pharmaceutical Publishing Co. Ltd., pp. 1218-1220
357. Tormey, D.C., Gray, R., Falkson, H.C., Gilchrist, K., Abeloff, M.D., Falkson, G. & Participating Investigators (1993) Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials. Recent Results Cancer Res., 127, 185-196
358. Tse, J. & Goldfarb, S. (1988) Immunohistochemical demonstration of estrophilin in mouse tissues using a biotinylated monoclonal antibody. J. Histochem. Cytochem., 36, 1527-1531
359. Tucker, M.J., Adam, H.K. & Patterson, J.S. (1984) Tamoxifen. In: Laurence, D.R., McLean, A.E.M. & Weatherall, M., eds, Safety Testing of New Drugs, New York, Academic Press, pp. 125-162
360. Uesugi, Y., Sato, T. & Iguchi, T. (1993) Morphometric analysis of the pelvis in mice treated neonatally with tamoxifen. Anat. Rec., 235, 126-130
361. Ugwumadu, A.H.N. & Harding, K. (1994) Uterine leimyomata and endometrial proliferation in postmenopausal women teated with the anti-oestrogen tamoxifen. Eur. J. Obstet. Gynecol., 54, 153-156
362. Ugwumadu, A.H.N., Bower, D. & Ho, P.K.-H. (1993) Tamoxifen induced adenomyosis and adenomyomatous endometrial polyp. Br. J. Obstet. Gynaecol., 100, 386-392
363. Ulibarri, C. & Micevych, P.E. (1993) Role of perinatal estrogens in sexual differentiation of the inhibition of lordosis by exogenous cholecystokinin. Physiol. Behav., 54, 95-100
364. United States Library of Medicine (1996) RTECS Database, Bethesda, MD
365. United States Pharmacopeial Convention (1994) The 1995 US Pharmacopeia, 23rd Rev./The National Formulary, 18th Rev., Rockville, MD, pp. 1477-1479
366. Uziely, B., Lewin, A., Brufman, G., Dorembus, D. & Mor-Yosef, S. (1993) The effect of tamoxifen on the endometrium. Breast Cancer Res. Treat., 26, 101-105
367. Vanchieri, C. (1993) European tamoxifen studies moving ahead. J. natl Cancer Inst., 85, 1450-1451
368. Vancutsem, P.M., Lazarus, P. & Williams, G.M. (1994) Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res., 54, 3864-3867
369. Vargas Roig, L.M., Lotfi, H., Olcese, J.E., Lo Castro, G. & Ciocca, D.R. (1993) Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma. Anticancer Res., 13, 2457-2464
370. Vickers, A.E. & Lucier, G.W. (1991) Estrogen receptor, epidermal growth factor and cellular ploidy in elutriated subpopulations of hepatocytes during liver tumor promotion by 17 alphaethinylestradiol in rats. Carcinogenesis, 12, 391-399
371. Vidal (1995) Dictionnaire Vidal, 71st Ed., Paris, Editions du Vidal, p. 144
372. de Vos, D., Guelen, P.J.M. & Stevenson; D. (1989) The bioavailability of Tamoplex (tamoxifen). Part 4. A parallel study comparing Tamoplex and four batches of Nolvadex in healthy male volunteers. Meth. Find. exp. clin. Pharmacol., 11, 647-655
373. Wakeling, A.E., O'Connor, K.M. & Newboult, E. (1983) Comparison of the biological effects of tamoxifen and a new antioestrogen (LY 117018) on the immature rat uterus. J. Endocrinol., 99, 447-453
374. Ward, H.W.C. (1973) Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br. med J., i, 13-14
375. Ward, R.L., Morgan, G., Dalley, D. & Kelly, P.J. (1993) Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Min., 22, 87-94
376. Watson, J., Anderson, F.B., Alam, M., O'Grady, J.E. & Heald, P.J. (1975) Plasma hormones and pituitary luteinizing hormone in the rat during the early stages of pregnancy and after postcoital treatment with tamoxifen (ICI 46,474). J. Endocrinol., 65, 7-17
377. Weckbecker, G., Tolcsvai, L., Stolz, B., Pollak, M. & Bruns, C. (1994) Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res., 54, 6334-6337
378. West, C.M.L., Reeves, S.J. & Brough, W. (1990) Additive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells. Cancer Lett., 55, 159-163
379. White, I.N.H., De Matteis, F., Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer, A. & Phillips, D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203
380. White, I.N.H., Davies, A., Smith, L.L., Dawson, S. & De Matteis, F. (1993) Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem. Pharmacol., 45, 21-30
381. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem. Pharmacol., 49, 1035-1042
382. Williams, G.M., Iatropoulos, M.J., Djordjevic, M.V. & Kaltenberg, O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317
383. Winterfeld, G., Hauff, P., Görlich, M., Arnold, W., Fichtner, I. & Staab, H.J. (1992) Investigations of droloxifene and other hormone manipulations on N-nitrosomethylurea-induced rat mammary tumours. I. Influence on tumour growth. J. Cancer Res. clin. Oncol., 119, 91-96
384. Wiseman, H. (1994) Tamoxifen: Molecular Basis of Use in Cancer Treatment and Prevention, Chichester, John Wiley
385. Wiseman, H., Paganga, G., Rice-Evans, C. & Halliwell, B. (1993) Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen. Biochem. J., 292, 635-638
386. Wolter, J., Ryan, W.G., Subbaiah, P.V. & Bagdade, J.D. (1988) Apparent beneficial effects of tamoxifen on serum lipoprotein subfractions and bone mineral content in patients with breast cancer (Abstract no. 34). Proc. Am. Soc. clin. Oncol., 7, 10
387. Wong, A. & Chan, A. (1993) Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study. Cancer, 71, 2200-2203
388. Wright, C.D.P., Garrahan, N.J., Stanton, M., Gazet, J.-C., Mansell, R.E. & Compston, J.E. (1994) Effect of long-term tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancer. J. Bone min. Res., 9, 153-159
389. Yager, J.D. & Shi, Y.E. (1991) Synthetic estrogens and tamoxifen as promoters of hepatocarcinogenesis. Prev. Med., 20, 27-37
390. Yager, J.D., Roebuck, B.D., Paluszcyk, T.L. & Memoli, V.A. (1986) Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats. Carcinogenesis, 7, 2007-2014
391. Yagoda, A., Abi-Rached, B. & Petrylak, D. (1995) Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Sem. Oncol., 22, 42-60
392. Yang, H.-H., Aulerich, R.J., Helferich, W., Yamini, B., Chou, K.C., Miller, E.R. & Bursian, S.J. (1995) Effects of zearalenone and/or tamoxifen on swine and mink reproduction. J. appl. Toxicol., 15, 223-232
393. Zemlickis, D., Lishner, M., Degendorfer, P., Panzarella, T., Sutcliffe, S.B. & Koren, G. (1992) Fetal outcome after in utero exposure to cancer chemotherapy. Arch. intern. Med., 152, 573-576
394. Zimniski, S.J. & Warren, R.C. (1993) Induction of tamoxifen-dependent rat mammary tumors. Cancer Res., 53, 2937-2939